Comparative Pharmacology
Head-to-head clinical analysis: MEDROXYPROGESTERONE ACETATE versus NORLUTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEDROXYPROGESTERONE ACETATE versus NORLUTIN.
MEDROXYPROGESTERONE ACETATE vs NORLUTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Medroxyprogesterone acetate is a progestin that binds to progesterone receptors, inhibiting gonadotropin secretion (LH, FSH) from the pituitary, thereby suppressing ovulation and altering the endometrial lining.
Synthetic progestin that binds to progesterone receptors, suppressing gonadotropin secretion and altering endometrial lining.
150 mg IM every 3 months for contraception; 400-1000 mg IM weekly for endometrial cancer; 5-10 mg PO daily for secondary amenorrhea.
5 mg orally three times daily for endometriosis; 5 mg orally daily from day 5 to day 25 of menstrual cycle for amenorrhea.
None Documented
None Documented
Terminal elimination half-life is approximately 12-17 hours after oral administration; with depot intramuscular injection, the half-life is prolonged (up to 50-60 days due to slow release from injection site).
Clinical Note
moderateMedroxyprogesterone acetate + Digoxin
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMedroxyprogesterone acetate + Digitoxin
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMedroxyprogesterone acetate + Deslanoside
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMedroxyprogesterone acetate + Acetyldigitoxin
Terminal elimination half-life: 5–14 hours (mean ~8 hours). Clinical context: short half-life necessitates daily dosing for contraceptive efficacy.
Primarily metabolized in the liver; metabolites are excreted in urine (50-70%) and feces (30-50%). Less than 5% excreted unchanged in urine.
Mainly renal as glucuronide and sulfate conjugates; approximately 70% renal, 30% fecal/biliary.
Category D/X
Category C
Progestin
Progestin
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Acetyldigitoxin."